UY30400A1 - Utilizacion de un antagonista de los receptores cb1 de los cannabinoides para la preparacion de medicamentos utiles para la prevencion y el tratamiento de la hipertrofia benigna de la prostata - Google Patents

Utilizacion de un antagonista de los receptores cb1 de los cannabinoides para la preparacion de medicamentos utiles para la prevencion y el tratamiento de la hipertrofia benigna de la prostata

Info

Publication number
UY30400A1
UY30400A1 UY30400A UY30400A UY30400A1 UY 30400 A1 UY30400 A1 UY 30400A1 UY 30400 A UY30400 A UY 30400A UY 30400 A UY30400 A UY 30400A UY 30400 A1 UY30400 A1 UY 30400A1
Authority
UY
Uruguay
Prior art keywords
antagonist
receptors
prevention
preparation
treatment
Prior art date
Application number
UY30400A
Other languages
English (en)
Inventor
Avallone Roberta
Guagnini Fabio
Croci Tiziano
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30400A1 publication Critical patent/UY30400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion tiene por objeto la utilizacion de un antagonista de los receptores CB1 de los cannabinoides, para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la hipertrofia benigna de la prostata.
UY30400A 2006-06-07 2007-06-07 Utilizacion de un antagonista de los receptores cb1 de los cannabinoides para la preparacion de medicamentos utiles para la prevencion y el tratamiento de la hipertrofia benigna de la prostata UY30400A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0605074A FR2902008A1 (fr) 2006-06-07 2006-06-07 Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate

Publications (1)

Publication Number Publication Date
UY30400A1 true UY30400A1 (es) 2008-01-31

Family

ID=37773101

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30400A UY30400A1 (es) 2006-06-07 2007-06-07 Utilizacion de un antagonista de los receptores cb1 de los cannabinoides para la preparacion de medicamentos utiles para la prevencion y el tratamiento de la hipertrofia benigna de la prostata

Country Status (19)

Country Link
US (1) US20090124643A1 (es)
EP (1) EP2037920A1 (es)
JP (1) JP2009539814A (es)
KR (1) KR20090016576A (es)
CN (1) CN101460169A (es)
AR (1) AR061236A1 (es)
AU (1) AU2007255265A1 (es)
BR (1) BRPI0711739A2 (es)
CA (1) CA2648645A1 (es)
CL (1) CL2007001632A1 (es)
EA (1) EA200870507A1 (es)
FR (1) FR2902008A1 (es)
IL (1) IL195079A0 (es)
MA (1) MA30850B1 (es)
MX (1) MX2008015474A (es)
NO (1) NO20084293L (es)
TW (1) TW200812583A (es)
UY (1) UY30400A1 (es)
WO (1) WO2007141413A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.

Also Published As

Publication number Publication date
WO2007141413A1 (fr) 2007-12-13
NO20084293L (no) 2008-12-22
JP2009539814A (ja) 2009-11-19
EA200870507A1 (ru) 2009-06-30
AU2007255265A1 (en) 2007-12-13
AR061236A1 (es) 2008-08-13
KR20090016576A (ko) 2009-02-16
CL2007001632A1 (es) 2008-01-18
CA2648645A1 (fr) 2007-12-13
EP2037920A1 (fr) 2009-03-25
MX2008015474A (es) 2009-01-12
TW200812583A (en) 2008-03-16
MA30850B1 (fr) 2009-11-02
US20090124643A1 (en) 2009-05-14
FR2902008A1 (fr) 2007-12-14
BRPI0711739A2 (pt) 2011-12-06
CN101460169A (zh) 2009-06-17
IL195079A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
DOP2015000264A (es) Derivados de azaadamantano y métodos de uso de los mismos
CL2007001269A1 (es) Compuestos derivados de heterociclos de nitrogeno, moduladores de vias de hedgehog; y uso para el tratamiento de cancer pancreatico, cancer de prostata, meduloblastoma, carcinoma celular basal y cancer pulmonar de celula pequena.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
BRPI0716210A2 (pt) Métodos, composições e aparelhos para tratar feridas com pressões diferentes da atmosférica
GT200900027A (es) Compuestos organicos
ECSP11011417A (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
UY3723Q (es) Aerosol
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
BRPI0815887A2 (pt) Uso de conduto metálico, processo e duto subterrâneo.
PA8778601A1 (es) Inhibidores de la unión entre hdm2 y el proteasoma
UY30511A1 (es) Agonistas de ep2
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
ECSP088315A (es) Moduladores de hexahidro-ciclooctil pirazol cannabinoide
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
CO6571898A2 (es) Composición pesticida y su uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130111